Compare HOWL & OFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOWL | OFS |
|---|---|---|
| Founded | 2017 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.5M | 69.7M |
| IPO Year | 2021 | 2012 |
| Metric | HOWL | OFS |
|---|---|---|
| Price | $0.61 | $4.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $6.50 | N/A |
| AVG Volume (30 Days) | ★ 935.7K | 110.3K |
| Earning Date | 11-04-2025 | 10-30-2025 |
| Dividend Yield | N/A | ★ 14.72% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.24 |
| Revenue | N/A | ★ $42,970,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $19.16 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.56 | $4.44 |
| 52 Week High | $2.38 | $9.80 |
| Indicator | HOWL | OFS |
|---|---|---|
| Relative Strength Index (RSI) | 30.66 | 34.90 |
| Support Level | $0.59 | $4.44 |
| Resistance Level | $0.74 | $4.66 |
| Average True Range (ATR) | 0.09 | 0.20 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 8.02 | 18.28 |
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.